The Psychosocial Burden of Drug-Resistant Epilepsy: A Call for Better Therapies

Introduction: Seizures Are Only Part of the Story

When a neurologist adjusts an epilepsy medication, they typically track one primary metric: seizure frequency. Did the seizures decrease? By how much? How many per month compared to last visit? These are the numbers that drive clinical decisions, and for good reason: seizure control is the immediate, measurable goal of treatment.

But for someone living with refractory epilepsy, seizure frequency is only one measure of how the condition is affecting their life. It doesn't capture the fear of losing consciousness in public. It doesn't reflect the grief that comes with surrendering a driver's license. It says nothing about the job a person left because unpredictable seizures made it impossible to stay. And it tells you very little about the depression, the social withdrawal, or the relationships that quietly fell apart under the weight of a condition nobody around them fully understood.

The psychosocial burden of drug-resistant epilepsy is enormous, pervasive, and systematically underdiscussed in clinical settings. It affects not just patients, but their families, caregivers, and communities. It is measurable, well-documented in the research literature, and not adequately addressed by the treatments currently available.

This is the fuller picture of uncontrolled epilepsy, and it is precisely why better therapies are not just a clinical priority, but a human one.

---

Part 1: Understanding What "Psychosocial" Actually Means in Epilepsy

What Does Psychosocial Burden Mean for Someone With Drug-Resistant Epilepsy?

The term "psychosocial" covers the intersection of psychological wellbeing and social functioning. For someone with refractory epilepsy, psychosocial burden refers to the cumulative emotional, cognitive, relational, and social consequences of living with seizures that cannot be controlled despite multiple medication trials.

This goes well beyond mood. It includes:

• How a person feels about themselves and their future (psychological dimension)
• How they interact with family, friends, and colleagues (social dimension)
• Whether they can work, drive, travel, or live independently (functional dimension)
• How they cope with fear, stigma, and unpredictability (existential dimension)

What makes the psychosocial burden of drug-resistant epilepsy distinct from the burden of well-controlled epilepsy is the element of failed expectation. A person who tries one medication and achieves seizure control still faces some psychosocial adjustment. But a person who has tried five or six medications over years, watched each one fail, and still cannot drive or work reliably faces something categorically different: a future without a clear treatment horizon.

That loss of hope is its own clinical problem, and it deserves to be treated as one.

How Is Psychosocial Burden Measured in Epilepsy Research?

Researchers and clinicians use several validated tools to quantify psychosocial outcomes in epilepsy:

• QOLIE-89 and QOLIE-31 (Quality of Life in Epilepsy inventories): Measure seizure worry, emotional wellbeing, cognitive function, social function, and energy and fatigue
• NDDI-E (Neurological Disorders Depression Inventory for Epilepsy): A validated six-item screening tool for depression specifically calibrated for epilepsy populations
• GAD-7 (Generalized Anxiety Disorder scale): Commonly used to screen for anxiety disorders
• Liverpool Seizure Severity Scale: Captures the subjective experience of seizure events, which influences psychosocial outcomes beyond seizure count
• CASI (Cognitive Assessment in Self-Reported Impairment): Measures perceived cognitive function, which is significantly affected by both epilepsy and antiseizure medications

When these tools are applied systematically to people with pharmacoresistant epilepsy, the results are consistent and alarming. Quality of life scores are substantially lower than in both the general population and in people with well-controlled epilepsy, across nearly every subscale.

---

Part 2: The Psychological Dimensions of Drug-Resistant Epilepsy

How Common Is Depression in People With Drug-Resistant Epilepsy?

Depression is the most prevalent psychiatric comorbidity in epilepsy, and its rates are dramatically elevated in refractory forms of the condition. Across multiple studies, approximately 30 to 55 percent of people with treatment-resistant epilepsy meet diagnostic criteria for a depressive disorder. In some tertiary epilepsy center populations, that rate approaches 60 percent.

To put that in perspective: the lifetime prevalence of major depressive disorder in the general US adult population is approximately 17 to 21 percent. Refractory epilepsy more than doubles that baseline risk, and in some populations triples it.

The relationship between epilepsy and depression is bidirectional and neurobiological, not simply psychological. Depression in this population is not just a reasonable emotional response to having a difficult condition. It reflects shared underlying neurobiology, including dysfunction in serotonergic circuits, disrupted limbic-cortical connectivity, and the effects of recurrent seizures on the hippocampus and prefrontal cortex. This distinction matters enormously for how depression should be understood and treated in this group.

People with uncontrolled epilepsy and co-occurring depression are not simply "understandably sad." They have two overlapping neurological conditions, both of which require active clinical attention.

Despite this, depression is persistently underscreened and undertreated in epilepsy clinical practice. Multiple studies have found that the majority of people with epilepsy who meet diagnostic criteria for depression have not been identified by their treating neurologists and are not receiving depression-specific treatment.

What Is the Link Between Drug-Resistant Epilepsy and Anxiety?

Anxiety disorders are nearly as prevalent as depression in this population, and in some ways more directly connected to the seizure experience itself. Roughly 25 to 50 percent of people with refractory epilepsy have a clinically significant anxiety disorder, most commonly generalized anxiety disorder, social anxiety disorder, or ictal and peri-ictal anxiety that occurs as part of the seizure itself.

Seizure-related anxiety has a specific character that distinguishes it from non-epileptic anxiety. The unpredictability of seizures, the loss of control they represent, and the potential for injury or embarrassment in public create a pattern of hypervigilance and avoidance that is both understandable and self-reinforcing.

Consider what this looks like in daily life:

• A person avoids swimming, bathing unsupervised, or cooking because of seizure-related injury risk
• They stop using public transportation because of fear of a seizure on a bus or subway
• They decline social invitations because they are anxious about having a seizure in front of others
• Over time, their world contracts. The avoidance that began as reasonable caution becomes a behavioral restriction that further isolates them

This is not irrational behavior. It is a predictable psychological response to an unpredictable medical reality. But when it becomes severe enough to restrict daily functioning, it constitutes a clinically significant anxiety disorder that requires direct treatment, not simply reassurance.

How Does Fear of SUDEP Affect Mental Health in Refractory Epilepsy?

SUDEP, Sudden Unexpected Death in Epilepsy, is one of the leading causes of premature death in epilepsy. Its rate is substantially higher in people with pharmacoresistant seizures, particularly those with frequent, uncontrolled generalized tonic-clonic episodes. For patients in this population, SUDEP risk is a genuine, evidence-based concern.

The communication of SUDEP risk creates an ethical and psychological challenge. Patients and their families deserve accurate information about their risk. At the same time, SUDEP-related fear is a significant contributor to anxiety, sleep disruption, and caregiver hypervigilance, particularly around nighttime seizures.

Parents of children with refractory epilepsy frequently describe monitoring their child's breathing during sleep, using seizure detection devices, and sleeping lightly or not at all. This sustained hypervigilance is itself a clinically significant burden, not just for caregivers but for the family system as a whole.

For adults who are aware of their own SUDEP risk, the psychological weight of that knowledge, combined with repeated medication failures and no clear treatment horizon, creates conditions in which suicidal ideation becomes a meaningful clinical concern. Research has found elevated rates of suicidal ideation in epilepsy populations, and this risk is higher in those with active, poorly controlled seizures.

What Is the Cognitive Impact of Drug-Resistant Epilepsy and Why Does It Matter Psychosocially?

Cognitive impairment in refractory epilepsy comes from multiple sources operating simultaneously:

Seizure-related cognitive effects: Recurrent seizures, particularly those involving the temporal lobe or with secondary generalization, produce cumulative effects on memory consolidation, attention, and processing speed. The postictal period (the recovery phase after a seizure) can include hours of confusion, fatigue, and memory impairment that disrupts daily function.

Antiseizure medication effects: The cognitive side effects of antiseizure medications are well-documented and include slowed processing speed, reduced working memory capacity, word-finding difficulties, and sedation. These effects are additive when multiple medications are used simultaneously, which is typical in drug-resistant epilepsy where polytherapy is the norm.

Underlying brain pathology: In many cases, the structural brain abnormality driving the seizures (hippocampal sclerosis, cortical dysplasia, cortical tubers) is itself associated with cognitive effects independent of the seizures or medications.

The combined cognitive impact is not subtle. People living with uncontrolled epilepsy commonly report difficulty following conversations, struggling to find words, forgetting appointments or medications, and taking much longer than before to complete tasks they previously found easy. These are not minor inconveniences. They have direct consequences for employment, academic performance, and self-concept.

The loss of cognitive sharpness is particularly distressing for people who remember a prior functional baseline, before epilepsy or before their medications changed. That comparison between who they were and who they feel they are now is a significant driver of depression and reduced self-efficacy in this population.

---

Part 3: The Social Dimensions of Drug-Resistant Epilepsy

How Does Drug-Resistant Epilepsy Affect Employment and Financial Stability?

Employment is one of the most concrete and measurable areas of psychosocial burden in refractory epilepsy, and the data are stark. People with uncontrolled epilepsy have employment rates substantially below both the general population and people with well-controlled epilepsy. Unemployment rates in this group are estimated at 25 to 50 percent, compared to general population rates of 3 to 6 percent in the US and Canada under normal economic conditions.

The reasons are multiple and overlapping:

• Seizure unpredictability makes sustained employment difficult in many job categories, particularly those involving machinery, heights, driving, or direct patient care
• Cognitive side effects of polytherapy reduce productivity and reliability in cognitively demanding work
• Frequent medical appointments at epilepsy centers disrupt work schedules
• Employer stigma, despite legal protections under the Americans with Disabilities Act in the US and the Canadian Human Rights Act, remains a real factor in hiring and retention decisions
• Disclosure anxiety: Many people with epilepsy face the difficult decision of whether to disclose their condition to an employer, knowing that disclosure may lead to discrimination despite legal protections

The financial consequences extend beyond lost wages. Medical costs for pharmacoresistant epilepsy are substantially higher than for the well-controlled condition. Emergency department visits after breakthrough seizures, neurology appointments, neuroimaging, medication costs for complex polytherapy regimens, and the evaluation and follow-up costs of surgical or device-based treatments add up over years.

In the United States, where medical debt is the leading cause of personal bankruptcy, the financial burden of a chronic condition like this one can be life-altering in ways that extend far beyond the direct health impacts.

How Does Losing a Driver's License Affect Quality of Life in Refractory Epilepsy?

Loss of driving privileges is one of the most frequently cited quality-of-life impacts in epilepsy, and it falls disproportionately on those with uncontrolled seizures. In the United States, seizure-free periods required before driving vary by state, ranging from 3 months to 12 months. In Canada, provincial regulations similarly require seizure-free periods before driving is permitted.

For people with refractory epilepsy, who by definition have not achieved sustained seizure control, the loss of a driver's license is often permanent or indefinitely extended.

The impact is not simply "inconvenience." In much of the United States and Canada, particularly outside major urban centers, driving is not optional. It is the primary means of accessing work, medical care, grocery stores, social activities, and family. Without it:

• Employment options narrow dramatically to jobs reachable by public transit or within walking distance
• Medical appointments require coordination with others, adding dependency and logistical complexity
• Social participation decreases, contributing to isolation
• The person becomes practically dependent on family members, friends, or paid services for daily transportation

That dependency, for many adults, is a significant source of psychological distress. The erosion of autonomy sits at the center of the quality-of-life loss in drug-resistant epilepsy, and the driving restriction is one of its most concrete expressions.

What Happens to Relationships and Social Life When Epilepsy Is Uncontrolled?

Social relationships under the strain of refractory epilepsy are affected in ways that compound over time. The effects differ across life stages, but they are present across the lifespan.

In childhood and adolescence:

Children with uncontrolled epilepsy face seizure-related embarrassment and stigma from peers, particularly if a seizure occurs at school or in a social setting. They may be excluded from activities that carry seizure-related risk, such as swimming, field trips, or sports. Cognitive and learning challenges associated with the condition and its medications create academic difficulties that further separate them from age-peers.

Adolescence, already a period of identity formation and social comparison, is particularly painful when refractory epilepsy is prominent. The restrictions the condition imposes, the visible difference from peers, and the potential for embarrassment in social settings contribute meaningfully to depression and social withdrawal.

In adulthood:

Adults with uncontrolled epilepsy describe reduced social networks, difficulty maintaining friendships, and often a reliance on a much smaller circle of people who understand and can accommodate the condition. Dating and romantic relationships present particular challenges: when and how to disclose the condition, how a partner handles witnessing a seizure, and the impact of epilepsy-related limitations on shared activities all require ongoing navigation.

For people in long-term relationships, the caregiving dynamic that refractory epilepsy often creates can strain partnerships in ways that neither person anticipated. A partner who must witness and manage seizures, take over responsibilities their spouse cannot safely perform, and accommodate the emotional variability of someone living with a poorly controlled neurological condition carries a burden that is rarely acknowledged in clinical settings.

How Severe Is the Caregiver Burden in Drug-Resistant Epilepsy?

Caregiver burden in refractory epilepsy, particularly for parents of children with treatment-resistant syndromes like Dravet syndrome or Lennox-Gastaut syndrome, is extreme by any metric studied.

Parents describe:

• Constant seizure vigilance, including nighttime monitoring for safety
• Work reduction or job loss to provide caregiving and attend frequent medical appointments
• Financial strain from medical costs combined with reduced household income
• Marital stress and divorce at rates above the general population
• Physical exhaustion from disrupted sleep and the physical demands of managing seizures
• Social isolation as family activities become restricted by the unpredictability of seizures
• Grief and anticipatory mourning for the life their child might have had

Siblings of children with refractory epilepsy are a population whose burden is particularly underappreciated. They grow up in households organized around a medical condition, may take on caregiving responsibilities that are not age-appropriate, and receive less parental attention during periods of medical crisis. The long-term psychological effects on siblings are documented but inadequately addressed by the medical system.

For adult caregivers, including spouses and adult children of people with refractory epilepsy, the burden is structurally similar. Studies using validated caregiver burden scales consistently find high levels of emotional exhaustion, reduced personal time, financial impact, and deterioration in the caregiver's own physical and mental health.

---

Part 4: The Clinical Gap — Why Is Psychosocial Burden Under-Addressed?

Why Do Neurologists Often Miss the Psychosocial Dimensions of Drug-Resistant Epilepsy?

This question is not an indictment of individual neurologists. It reflects systemic problems in how epilepsy care is structured and what it is optimized to deliver.

Appointment time constraints: Neurology appointments in most US and Canadian health systems are scheduled for 20 to 40 minutes. In that window, a neurologist managing complex refractory epilepsy must review seizure logs, evaluate medication response, assess side effects, order imaging or labs if indicated, discuss any new developments, and document the encounter. Systematic psychosocial screening gets squeezed out of visits that are already over capacity.

Training and scope: Neurologists are trained in the management of neurological disease. Depression, anxiety, social function, and family burden fall into psychiatry, psychology, and social work. The structural separation between neurology and behavioral health in most healthcare systems means that psychosocial needs identified in a neurology appointment frequently go without a clear referral pathway.

The "at least your seizures are fewer" problem: Neurologists naturally frame progress in terms of the primary outcome measure they track, which is seizure frequency. A patient whose seizures decreased from ten per month to five per month has "improved" from a clinical standpoint, even if their quality of life has not improved proportionally because the five remaining seizures still prevent driving and employment. The gap between clinical metrics and lived experience is real, and bridging it requires deliberate effort.

Patient underreporting: Many people with refractory epilepsy underreport depression, anxiety, and psychosocial struggles during neurology appointments for several reasons: they may not recognize these as part of their epilepsy condition; they may not want to be seen as "not coping"; or they may have treated seizure management as the only item on the agenda.

What Are the Common Clinical Mistakes Made in Managing the Psychosocial Burden of Refractory Epilepsy?

Treating depression as inevitable rather than treatable. Depression in this population is not simply an expected response to a hard diagnosis. It has neurobiological underpinnings that respond to treatment, including psychological interventions and, in some cases, antidepressant medications. Treating it as an expected feature of the condition rather than a comorbidity requiring active management perpetuates unnecessary suffering.

Using sedating antidepressants without accounting for cognitive burden. When depression in drug-resistant epilepsy is treated pharmacologically, the choice of antidepressant matters. Tricyclic antidepressants lower the seizure threshold and are generally avoided. Sedating agents further compound the cognitive side effects already present from antiseizure polytherapy. SSRIs are more commonly used, though their interaction with specific antiseizure medications requires careful attention.

Not addressing caregiver mental health as part of the care plan. Caregiver burnout is a predictable consequence of managing refractory epilepsy over years or decades. Burned-out caregivers provide lower-quality care, are at higher risk of their own mental health crises, and are less able to advocate effectively for the person they care for. Yet caregiver mental health is rarely addressed proactively in standard epilepsy care settings.

Delaying access to social work and community support. Social workers embedded in epilepsy care teams can address employment support, disability applications, transportation assistance, and community resources. Their involvement is most valuable before a crisis, not after. Yet many families navigating refractory epilepsy go years without a social work referral.

Focusing exclusively on seizure count as the outcome measure in treatment decisions. A treatment that reduces seizures by 30 percent but causes cognitive slowing, weight gain, and fatigue may represent a net negative from the patient's quality-of-life perspective, even if it registers as a success on the standard seizure log. Incorporating patient-reported outcome measures, including quality-of-life scales, into routine clinical decision-making would more accurately reflect the full impact of treatment choices.

---

Part 5: Comparing Psychosocial Outcomes — Controlled vs. Drug-Resistant Epilepsy

How Different Is Life With Controlled Epilepsy vs. Refractory Epilepsy?

The table below summarizes the psychosocial contrast between these two groups, based on the published literature:

Psychosocial Domain

Well-Controlled Epilepsy

Drug-Resistant Epilepsy

Depression prevalence

~20-25%

~30-55%

Anxiety disorder prevalence

~15-25%

~25-50%

Employment rate

~60-70% of peers

~50-75% lower than peers

Independent driving

Possible after seizure-free period

Rarely achievable

Social participation

Moderately reduced

Severely reduced

Cognitive complaints

Mild to moderate

Moderate to severe

Caregiver burden

Present

Substantially higher

Quality of life scores (QOLIE)

Moderately impaired

Severely impaired

Suicidal ideation risk

Elevated vs. general population

Further elevated

SUDEP risk

Low to moderate

Substantially elevated

Healthcare costs

Elevated vs. general population

Substantially higher

Relationship strain

Moderate

Severe

This contrast illustrates why refractory epilepsy is not simply a more challenging version of the controlled form. It is a condition with a categorically different psychosocial profile, requiring a categorically different level of multidisciplinary support.

---

Part 6: The Call for Better Therapies — What Does "Better" Actually Mean?

What Would a Better Therapy for Drug-Resistant Epilepsy Look Like?

When patients, families, and researchers call for better therapies, the conversation often focuses on seizure frequency. A better drug, in this framing, is one that reduces seizures when existing drugs have failed. That is necessary, but it is not sufficient.

A genuinely better therapy would:

Address more than seizures. The most meaningful gap in current pharmacology is not that no drug reduces seizures in refractory patients. Several antiseizure medications are partially effective. The gap is that almost none of them address the anxiety, depression, cognitive burden, and impulse dysregulation that compound the seizure burden. A drug that addresses both seizure activity and the neuropsychiatric features driving psychosocial impairment would represent a genuinely meaningful advance over the current model.

Be safe for chronic use. Refractory epilepsy is a lifelong condition. A therapy designed for months of use is structurally mismatched to the clinical reality. The ideal drug is one that can be used continuously, without tolerance, without cumulative organ toxicity, and without progressive side effects that accumulate over years.

Carry a tolerable cognitive side-effect profile. The cognitive burden of antiseizure polytherapy is itself a major driver of psychosocial impairment. A new antiseizure drug that reduces seizures but adds cognitive load to an already heavily medicated patient has not solved the quality-of-life problem. It has traded one dimension of it for another.

Work through a genuinely different mechanism. The consistent failure rate of 30 to 35 percent across all generations of antiseizure drugs suggests that the dominant mechanisms (sodium channel blockade, calcium channel modulation, GABA potentiation) are insufficient for a substantial subset of the epilepsy population. New mechanisms, including serotonin receptor-targeted approaches, mTOR inhibition, and gene-based therapies, offer the possibility of reaching patients whose epilepsy was never going to respond to a channel blocker.

Why Is Serotonin Receptor-Targeted Therapy a Scientifically Credible Direction for Drug-Resistant Epilepsy?

The serotonin system's role in seizure modulation is well-established and often underappreciated in the mainstream epilepsy conversation. The 5-HT2C receptor subtype, concentrated in the hypothalamus and limbic system, plays a documented role in seizure threshold regulation. The clinical validation of this came with the FDA approval of fenfluramine for Dravet syndrome, a drug whose anticonvulsant mechanism operates substantially through serotonin receptor activity.

Fenfluramine's approval was a scientific proof-of-concept for the serotonin pathway in refractory epilepsy. But fenfluramine itself carries limitations, including cardiac side effects at higher doses and a regulatory history that complicates broader use.

The next step, which is where precision pharmacology enters the picture, is to develop selective serotonin receptor agonists that activate the anticonvulsant 5-HT2C pathway without activating the cardiac-risk-associated 5-HT2B receptor. This is precisely the direction being pursued at Bright Minds Biosciences, where the drug development program in refractory epilepsy is built on selective serotonin receptor agonism as its core mechanism.

What makes this approach particularly compelling from a psychosocial burden standpoint is the dual relevance of the 5-HT2C receptor. It is not only involved in seizure threshold regulation. It also modulates anxiety, impulsivity, and mood, all of which are central dimensions of the psychosocial burden documented throughout this article. A drug that addresses seizure control and neuropsychiatric comorbidity through a single molecular mechanism would represent a categorically different kind of advance than another antiseizure drug that reduces seizure count without touching quality of life.

Bright Minds Biosciences' approach is grounded in the principle that patients failed by existing therapies deserve drugs designed with their full clinical picture in mind, not just their seizure diary.

What Non-Pharmacological Approaches Address the Psychosocial Burden of Refractory Epilepsy?

The call for better therapies extends beyond pharmacology. The psychosocial burden of drug-resistant epilepsy is also addressed, and inadequately so, by psychological, social, and structural interventions:

Coordinated multidisciplinary care teams at comprehensive epilepsy centers, including embedded neuropsychologists, social workers, and psychiatrists, produce better patient-reported outcomes than neurology-only care. The infrastructure for this exists in major epilepsy centers but is not uniformly accessible across the US and Canada.

Cognitive behavioral therapy (CBT) adapted for epilepsy has demonstrated meaningful improvements in depression and anxiety outcomes in epilepsy populations. Mindfulness-based stress reduction programs have also shown benefit. The challenge is access: the number of therapists with specific expertise in epilepsy-related psychological care is limited.

Peer support and patient community programs through organizations like the Epilepsy Foundation in the US and Epilepsy Canada provide social connection, shared experience, and practical knowledge exchange that the clinical system does not and cannot replicate. Engagement with peer support communities is associated with better coping outcomes in chronic disease populations.

Structured family support and caregiver programs that address caregiver burnout, education about epilepsy management, and psychological support for the family unit improve outcomes for both caregivers and patients. These programs exist through epilepsy foundations and some specialized care centers but are not uniformly integrated into standard care.

Vocational rehabilitation services can help people with refractory epilepsy identify employment compatible with their functional capacity, access workplace accommodations, and navigate disability systems when employment is not feasible. These services exist through state vocational rehabilitation agencies in the US and provincial programs in Canada but are significantly underused by the epilepsy population.

---

Common Misconceptions About the Psychosocial Burden of Drug-Resistant Epilepsy

Is Depression in Refractory Epilepsy Just a Normal Emotional Response?

No, and this misconception matters clinically. While it is entirely understandable that someone with a poorly controlled chronic neurological condition might feel depressed, depression in epilepsy has neurobiological underpinnings that go beyond a psychological reaction to difficult circumstances. The same brain circuit disruptions that generate seizures, particularly in temporal and limbic regions, also affect the neural substrates of mood. Treating epilepsy-associated depression as simply "expected" leads to undertreatment of a clinically significant, independently diagnosable condition.

Does Addressing Mental Health "Distract" From Epilepsy Treatment?

This framing sets up a false choice. Untreated depression and anxiety in refractory epilepsy worsen seizure outcomes, reduce treatment adherence, increase healthcare use, and reduce the effectiveness of all clinical interventions. Addressing mental health in epilepsy is not a secondary concern that diverts resources from seizure management. It is a direct component of optimizing neurological outcomes.

Will Psychological Support Reduce Seizures?

Not directly, as a rule. Psychological support does not replace antiseizure medication or surgical treatment. However, stress is a significant seizure trigger in many people with epilepsy, and anxiety and sleep disruption, both of which are targets of psychological intervention, can lower seizure threshold in susceptible individuals. Treating the psychosocial burden is not an alternative to treating the seizures. It is a parallel and complementary clinical priority.

Is the Psychosocial Burden of Drug-Resistant Epilepsy Primarily a US Healthcare Problem?

The psychosocial burden of refractory epilepsy is documented across health systems, including Canada's publicly funded model. While US patients face additional financial pressures from medical costs and insurance complexities, the social isolation, cognitive burden, driving restrictions, psychiatric comorbidities, and caregiver burden described in this article are present regardless of healthcare system. Canadian families face the same neurological reality, and while some financial pressures are reduced by universal coverage, access to specialist care in rural and remote areas of Canada is often more restricted than in the US.

---

Frequently Asked Questions

What percentage of people with drug-resistant epilepsy have depression or anxiety?

Approximately 30 to 55 percent of people with refractory epilepsy meet diagnostic criteria for a depressive disorder, and 25 to 50 percent have a clinically significant anxiety disorder. These rates are two to three times higher than in the general population and notably higher than in people with well-controlled epilepsy. Depression and anxiety are not incidental features of the condition. They are documented comorbidities with neurobiological as well as psychological contributors.

Why doesn't my neurologist ask about my mental health during appointments?

Most epilepsy neurology appointments are structured around seizure management, which is the primary medical goal of the visit. Time constraints, the separation of neurology and behavioral health services, and the fact that patients often do not spontaneously volunteer mental health concerns all contribute to this gap. If your mental health is not being addressed, bring it up directly at your next appointment. A request for a referral to a neuropsychologist or behavioral health specialist embedded in your epilepsy team is entirely appropriate.

What should I do if I think I have depression alongside my epilepsy?

Talk to your neurologist or primary care physician directly. Mention that you have been experiencing persistent low mood, loss of interest in activities, fatigue, or other depression symptoms. You can ask for a referral to a psychiatrist or psychologist, or for the NDDI-E screening tool to quantify your symptoms. Depression in the context of epilepsy is complex enough that a psychiatrist with experience in neuropsychiatry is the most appropriate specialist to guide medication decisions.

Does drug-resistant epilepsy affect memory and thinking?

Yes, and significantly. Cognitive impairment in refractory epilepsy comes from multiple overlapping sources: the direct effects of recurrent seizures on brain tissue (particularly in the hippocampus and frontal lobe), the cognitive side effects of antiseizure medications (especially polytherapy regimens), and the underlying brain pathology driving the seizures. Memory, processing speed, word-finding, and executive function are the most commonly affected domains. Neuropsychological testing can characterize the specific pattern of cognitive impairment, which can help guide treatment decisions and workplace or academic accommodations.

How does refractory epilepsy affect family members and caregivers?

The impact on family members and caregivers is substantial and well-documented. Primary caregivers, typically parents of children with refractory epilepsy or spouses of affected adults, face disrupted sleep, reduced employment opportunities, financial strain, elevated rates of depression and anxiety, and social isolation. Siblings of children with uncontrolled epilepsy carry psychological burdens that are rarely addressed. Caregiver wellbeing should be actively monitored and supported as part of any comprehensive epilepsy care plan.

Are there new drugs in development that address both seizures and mental health in epilepsy?

Yes, and this is one of the most scientifically promising directions in the field. Serotonin receptor-targeted therapies, particularly selective 5-HT2C agonists, offer a mechanism that is relevant to both seizure threshold regulation (validated by fenfluramine's approval for Dravet syndrome) and to the neuropsychiatric features of epilepsy, including anxiety and mood dysregulation. Bright Minds Biosciences is actively developing a selective 5-HT2C agonist designed for chronic use, specifically for populations with refractory epilepsy. Information about their clinical programs is available at brightmindsbio.com.

What resources are available for people with drug-resistant epilepsy and their families in the US and Canada?

United States:

• Epilepsy Foundation (epilepsy.com): patient education, support groups, advocacy
• American Epilepsy Society: clinical guidelines and specialist resources
• NIH National Institute of Neurological Disorders and Stroke: research and clinical trial information
• Dravet Syndrome Foundation: for families managing Dravet syndrome specifically

Canada:

• Epilepsy Canada (epilepsy.ca): national patient organization
• Provincial epilepsy associations in Ontario, British Columbia, Alberta, and other provinces
• Canadian League Against Epilepsy: clinical and research resources
• HealthlinkBC and provincial health navigation services

---

Conclusion: The Seizure Diary Is Not Enough

The measure of how well epilepsy care is working cannot be reduced to how many seizures a person had last month. For the roughly one in three people with epilepsy in the United States and Canada whose seizures persist despite multiple treatments, the burden extends to every part of their lives, and the clinical response needs to extend there too.

Better therapies for drug-resistant epilepsy mean drugs that work through genuinely different mechanisms, designed for a lifetime of use, tolerated without cognitive cost, and relevant to the neuropsychiatric dimensions of the condition, not just the seizure count. They also mean clinical care models that systematically screen for depression and anxiety, connect patients with psychological and social support, and measure outcomes in terms of quality of life, not just the epilepsy diary.

The science to support this broader approach is available. The patient need is documented. What remains is the will to treat refractory epilepsy as what it is: a complex, multi-dimensional condition whose treatment must be equally multi-dimensional.

At Bright Minds Biosciences, this is not an abstract principle. The selective serotonin receptor agonist program targeting refractory epilepsy is built on the understanding that the people this condition affects deserve a drug designed for their full clinical reality, not just the seizure component of it.